AdaptHealth Corp. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
AdaptHealth Corp. agreed to sell its diabetes medical device and services business to RGH Enterprises LLC for a base purchase price of $235 million, plus/minus a Net Working Capital adjustment (target $71.289 billion). The deal includes $8M adjustment escrow and $18.8M indemnification escrow. Closing is expected on the first business day of a month following satisfaction of conditions. The transaction covers all diabetes-related assets, contracts, and assumed liabilities, with Seller retaining excluded assets and liabilities.
Why this rating
Asset sale of single business line (~$235M base price ~24% of $1B market cap) is material but not transformational. Typical M&A transaction structure with standard reps, warranties, indemnification.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.